Microscopic Polyangiitis (original) (raw)

Continuing Education Activity

Microscopic polyangiitis (MPA) is a small vessel necrotizing vasculitis that falls within a larger spectrum of disorders known as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides. This group also includes granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, MPA, and renal-limited vasculitis. MPA is a complex disorder that can affect any organ system, presenting with a wide range of symptoms.

Early diagnosis and treatment are crucial for improving outcomes, as immunosuppressive therapy is most effective when initiated before significant organ damage occurs. Treatment is typically divided into induction and maintenance phases, utilizing medications such as cyclophosphamide, glucocorticoids, and rituximab. Numerous trials have explored the most effective treatment regimens for various clinical scenarios. A comprehensive evaluation—including clinical, radiological, histopathological, and laboratory assessments—is essential for accurate diagnosis and effective management. This activity reviews the etiology, epidemiology, pathogenesis, histological findings, evaluation, and management of MPA, emphasizing the critical role of the interprofessional team in recognizing and managing this condition.

Objectives:

Access free multiple choice questions on this topic.

Introduction

Microscopic polyangiitis (MPA) is a small vessel necrotizing vasculitis that falls within a larger spectrum of disorders known as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides. This group also includes granulomatosis with polyangiitis (GPA), MPA, eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss disease), and renal limited vasculitis. This classification of vasculitides is based on the type of vessels involved and the underlying etiology, as established by the International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides (CHCC 2012).[1]

The term "microscopic polyangiitis" was first described as "microscopic polyarteritis" and introduced in the literature by Davson in 1948 to describe the pattern of glomerulonephritis observed in patients with polyarteritis nodosa. This condition was later described as a pattern of necrotizing vasculitis without immune complex deposition, primarily affecting small vessels such as the capillaries, venules, and arterioles. The disease commonly involves glomerulonephritis, pulmonary capillaritis, and other systemic capillary beds, with considerable overlap with GPA.

The absence of granulomatous inflammation in the upper respiratory tract and the presence of pulmonary capillaritis help differentiate MPA from GPA. MPA is more likely to have renal involvement than GPA. MPA is part of a group of disorders known as pulmonary-renal syndrome, which also includes GPA, Goodpasture disease, and systemic lupus erythematosus.[2][3] While ANCAs have a central role in the pathogenesis of ANCA-associated vasculitis, they are neither necessary nor sufficient to cause the disease patterns of ANCA-associated vasculitides. Clinical symptoms and biopsy results are equally important for diagnosis. The role of ANCAs and the distinctions between the various ANCA-associated vasculitides are also discussed in this activity.

Please refer to the following StatPearls' companion resources for further information:

Etiology

The etiopathogenesis of MPA and related vasculitides has largely been attributed to ANCAs, which are host-derived autoantibodies targeting normally shielded neutrophilic antigens. These antibodies react against primary granules in neutrophils and monocytes. The formation of these antibodies has been hypothesized to be a 2-step process.[4] In the first step, neutrophils are exposed to inflammatory cytokines, leading to the surface expression of antigens such as myeloperoxidase (MPO). Next, predisposing genetic, environmental, and other factors lead to ANCA production. In the second step, these ANCAs damage the host vasculature by triggering inflammation and cytokine production.[5]

Although anti-MPO is the primary ANCA associated with MPA, anti-proteinase 3 (PR3) can also be present in some cases. Estimates suggest that approximately 70% of patients with MPA are anti-MPO–positive, 20% are anti-PR3–positive, and 10% are ANCA-negative.[6] Less specific ANCA antigens include cathepsin G, lactoferrin, elastase, defensin, α-enolase, moesin, leukocidin, and bactericidal permeability increasing protein, although their pathogenicity is considered to be low.[6]

Lysosomal-associated membrane protein 2 (LAMP-2) antibodies are of particular interest in ANCA-associated vasculitis because they are present in patients with both anti-MPO and anti-PR3 antibodies and may contribute to the disease pathology. Moreover, LAMP-2 antibodies have been detected in patients with active ANCA-associated vasculitis who are negative for MPO and PR3 antibodies. Some evidence suggests that LAMP-2 antibodies may correlate better with disease activity than anti-MPO or anti-PR3 antibodies.[7][8]

About 90% of patients with active MPA test positive for ANCA; however, not all cases of ANCA positivity correlate with active disease. This suggests that other factors may also contribute to the disease's etiopathogenesis. These factors include (but are not limited to):

Epidemiology

Due to the recent differentiation of MPA from other ANCA-associated vasculitides, comprehensive demographic data for its prevalence in the US population are not widely available. A study conducted in Rochester, Minnesota, over a 20-year period estimated the annual incidence of ANCA-associated vasculitis at 3.3 per 100,000, with a prevalence of 42.1 per 100,000. The incidence of GPA and MPA was approximately 1.5 per 100,000.[12] An increase in the prevalence of MPA over the past 2 decades is likely due to improved recognition and the availability of ANCA testing. The global incidence of MPA is estimated to be 20 per million.[6]

Evidence suggests that MPA is more common in China and Japan, whereas GPA is more prevalent among populations of European descent.[6] The median age of onset for MPA is between 50 and 60. The disease appears to have about equal prevalence between males and females.[8]

Pathophysiology

While anti-MPO is the primary ANCA associated with MPA, anti-PR3 is also present in some cases. Notably, it is estimated that in MPA, approximately 70% of patients are anti-MPO–positive, 20% are anti-PR3–positive, and 10% are ANCA-negative.[6]

The clinical manifestations of MPA result from the activation of primed neutrophils and MPO-ANCA, which interact with receptors on the endothelial surface.[13] This process leads to a range of symptoms affecting the renal, pulmonary, and other capillary beds. Patients may present with an insidious onset of systemic signs such as fever, malaise, or weight loss; however, the onset is more commonly acute, with complaints of arthralgia and flu-like symptoms. MPA is a small vessel vasculitis characterized by pauci-immune, necrotizing inflammation without clinical or pathological evidence of granulomatous involvement, often leading to necrosis and bleeding.[6]

Renal manifestations are extremely common in MPA, with 80% to 90% of individuals experiencing some form of glomerulonephritis at onset or as the disease progresses. The most common renal manifestation is a "pauci-immune" form of rapidly progressive glomerulonephritis. Clinical presentations can range from asymptomatic hematuria, sub-nephrotic proteinuria, and elevated serum creatinine to overt renal failure. Pulmonary manifestations often include alveolar hemorrhage, which may sometimes be the first presenting symptom of the disease.[14]

Histopathology

Histopathological evidence of vasculitis is the gold standard for confirming the diagnosis of MPA and other ANCA-associated vasculitides. The most commonly sampled tissues are from the kidneys, skin, and lungs. Diffuse capillaritis is a typical pulmonary finding in patients with MPA, distinguishing it from GPA, which is characterized by the presence of granulomatous lesions. Skin biopsy yields acute or chronic leukocytoclastic vasculitis with neutrophilic infiltrate in the narrow caliber vessels of the superficial dermis. Renal biopsy findings in MPA typically range from mild focal or segmental to diffuse necrotizing and sclerosing glomerulonephritis, often presenting as crescentic glomerulonephritis. These biopsies usually show minimal to no immune complex deposits on light and immunofluorescent microscopy, a characteristic described as "pauci-immune" (see Image. Histopathological Changes in Microscopic Polyangiitis Showing Fibrosis).[15]

The importance of renal biopsy is underscored by the fact that the severity of renal involvement observed on histopathological evaluation correlates closely with clinical disease activity.[16] This makes biopsy a crucial tool for guiding the management of the condition and decisions regarding tapering immunosuppressive therapy. In some cases, the presence of immune complex deposits in the glomeruli may be associated with more severe systemic signs and symptoms. Please see StatPearls' companion resource, "Rapidly Progressive Glomerulonephritis," for more information.

History and Physical

Patients with MPA may present with constitutional symptoms, including insidious onset fever, arthralgia, myalgia, and weight loss. Other manifestations include urinary abnormalities, cough with or without hemoptysis, skin examination findings consistent with palpable purpura, mononeuritis multiplex, seizures, other nonspecific neurological complaints, abdominal pain, gastrointestinal bleeding, sinusitis, and chest, testicular, and ocular pain. Some patients may present with acute onset of fulminant disease with frank hemoptysis, hematuria, or even renal failure.

Renal Manifestations

The primary renal feature of MPA is rapidly progressive glomerulonephritis.[17] Previous studies reported that 80% to 90% of patients with MPA experience renal manifestations, which can range from asymptomatic urinary sediment to end-stage renal failure requiring renal replacement therapy. Common clinical features of renal involvement due to glomerulonephritis include microscopic hematuria, proteinuria, and the presence of granular or red blood cell (RBC) casts in the urine.[18]

Pulmonary Manifestations

Pulmonary involvement is thought to be observed in 25% to 55% of cases. However, pulmonary symptoms may be more common than previously thought. A single-center study found that 80% of MPA patients were observed to have symptoms of pulmonary involvement, and 92% were found to have radiographic changes.[19] Although the most common pulmonary feature is diffuse alveolar hemorrhage, some patients may develop chronic interstitial fibrosis, causing respiratory failure.[20] Common manifestations of alveolar hemorrhage include hemoptysis, cough, dyspnea, and pleuritic chest pain.[21] Unlike GPA and EGPA, upper respiratory tract signs are rare.

Skin Manifestations

Skin lesions are observed in 30% to 60% of patients with MPA, and these lesions are the initial presenting feature in 15% to 30% of cases.[22][23] These skin manifestations include palpable purpura, livedo reticularis, urticaria, nodules, and ulcers with necrosis. Additionally, skin manifestations have been associated with joint pain in patients with MPA (see Image. Typical Skin Manifestations Observed in Microscopic Polyangiitis).[24]

Gastrointestinal Manifestations

Abdominal pain is the most common gastrointestinal symptom in MPA. Although gastrointestinal bleeding can occur, massive hemorrhage is rare.[25]

Neurological Manifestations

Neurological involvement is common in MPA, with peripheral neuropathy occurring more frequently than central nervous system (CNS) involvement. Predominant peripheral nervous system features include distal symmetrical polyneuropathy and mononeuritis multiplex. Sural nerve biopsies often reveal necrotizing vasculitis in up to 80% of cases, and nerve conduction studies may show acute axonopathy.[26] Rarely, patients may present with posterior reversible encephalopathy syndrome.[27] CNS manifestations can vary and include cerebral hemorrhage, nonhemorrhagic cerebral infarctions, and pachymeningitis.[28]

Physical Examination

Findings from the physical examination of a patient with MPA may reveal systemic signs such as general malaise, fever, or weight loss. Skin examination findings may include leukocytoclastic angiitis, palpable purpura, livedo reticularis, skin ulcerations, necrosis, gangrene, necrotizing nodules, digital ischemia, and urticaria. Pulmonary examination may reveal rales or bronchial breath sounds, particularly in cases of pulmonary capillaritis. Neurological examination might demonstrate motor or sensory deficits localized to a particular dermatome. Cardiovascular findings may include hypertension, signs of heart failure, myocardial infarction, and pericarditis. Findings from the gastrointestinal examination include bleeding, bowel ischemia, and perforation. The ocular examination may reveal retinal hemorrhage, scleritis, and uveitis. Other physical findings will vary depending on the involved vascular bed.

Evaluation

Evaluating a patient with suspected MPA requires a comprehensive clinical, radiological, histopathological, and laboratory assessment. The initial step is a detailed clinical evaluation to determine the site and extent of involvement across various organ systems.

Laboratory Studies

As noted above, although anti-MPO is the primary ANCA associated with MPA, anti-PR3 can also be present in some cases. ANCA levels are most closely correlated with renal activity compared to other organ systems.[8] Other useful laboratory evaluations include:

Imaging Studies

A chest radiography and computed tomography (CT) scan of the chest should be obtained to assess for pulmonary lesions in patients presenting with hemoptysis or pulmonary fibrosis.[29] These imaging studies help differentiate between GPA and MPA, as GPA often shows cavitary and nodular lesions on radiological evaluation. A CT scan of the abdomen may also be performed to evaluate for pancreatitis or mesenteric angiography to distinguish MPA from polyarteritis nodosa.[30]

Other Studies

Histopathological Evaluation

A histopathological specimen (skin, renal, or lung biopsy) should be obtained whenever possible to identify evidence of vasculitis and immune deposits. The extent of inflammation observed on renal biopsy can be used to assess disease activity and guide treatment decisions.

Treatment / Management

Currently, the American College of Rheumatology and the European Alliance of Associations for Rheumatology (ACR/EULAR) are developing criteria for the treatment of ANCA-associated vasculitis. Based on new clinical trial data, recent recommendations suggest classifying disease manifestations into organ/life-threatening or non-organ/life-threatening categories rather than "severe" or "not severe." Examples of organ/life-threatening manifestations include glomerulonephritis, pulmonary hemorrhage, cardiac involvement, and retroorbital disease. Non-organ/life-threatening manifestations include skin involvement, myositis, and non-cavitating pulmonary nodules.[32]

The treatment of MPA involves using immunosuppressive agents in various combinations, divided into two phases: induction and maintenance. Commonly used agents include cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and, when indicated, plasmapheresis.

The 2022 EULAR recommendations for the management of ANCA-associated vasculitis apply to both GPA and MPA.[32] Treating EGPA follows a different set of guidelines. A key distinction between GPA and MPA is that patients with the clinical syndrome of GPA and PR3-ANCA positivity have a higher relapse risk compared to those with MPA or anti-MPO positivity. Additionally, persistent ANCA positivity, despite clinical remission, is associated with an increased risk of relapse.[32] Although extending immunosuppressive therapy beyond 24 months may reduce relapse risk, the heightened risk of infection may not warrant this prolonged treatment course.

The 2022 EULAR recommendations include:

Differential Diagnosis

Many conditions may mimic ANCA-associated vasculitis/MPA and must be excluded before establishing a diagnosis. Some of these processes include:

Infectious Etiologies

Malignancies

Drug Toxicities

Other Autoimmune Conditions

Toxicity and Adverse Effect Management

The immunosuppressive agents used in managing ANCA-associated vasculitis have severe adverse effects, which may be even more debilitating than the manifestations of the disease.

Glucocorticoids

Cyclophosphamide

Methotrexate

Azathioprine

Rituximab

Prognosis

The 5-year estimated survival rate for patients with MPA ranges from 45% to 76%, which is significantly worse than that for GPA or EGPA, largely due to renal disease.[6][40]

Long-term morbidity in a cohort of 296 patients with MPA or GPA was associated with the severity of the primary disease, the number of relapses, older age, and the duration of glucocorticoid treatment. In a 7-year follow-up post-diagnosis, the mean duration of glucocorticoid therapy was 40.4 months.[41]

Complications

If left untreated, MPA can lead to permanent organ damage, with kidney failure being the most common complication. Other complications depend on the specific organ systems involved. Research has shown that older age, diastolic hypertension, and positive PR3-ANCA status correlate with an increased risk of cardiovascular events.[42]

The medications used to treat MPA can also lead to significant adverse effects. For instance, cyclophosphamide is strongly associated with an increased risk of bladder cancer. Additionally, steroids are known to cause bone loss, hyperglycemia, muscle weakness, and skin issues.

Deterrence and Patient Education

Adherence to medication and therapy is crucial, along with regular follow-ups. Patients should be closely monitored during the prolonged course of immunosuppressive treatment, which typically extends for over a year, with disease activity assessed through ANCA levels. It's essential to inform patients about the potential adverse effects of their medications and emphasize the importance of reporting them promptly. Additionally, patients should be made aware that relapse is common, so they understand the necessity of ongoing follow-up even after achieving remission, as they are not "cured."

Enhancing Healthcare Team Outcomes

MPA is a complex condition best managed by a multidisciplinary team due to its varied clinical presentation and the need for patient-specific treatment. Effective communication among an interprofessional medical team—including clinicians, nurses, radiologists, pathologists, and pharmacists—is essential for optimal care. Nurses are critical in monitoring and documenting vital signs, especially urine output, which is crucial for guiding treatment decisions. Radiologists contribute by performing image-guided tissue biopsies, which are then analyzed by pathologists to confirm the presence of disease. Proper dosing and dispensing of immunosuppressive agents by pharmacists are crucial for the successful induction and maintenance of remission. Failure in this area can result in severe systemic adverse effects. Additionally, pharmacists must perform thorough medication reconciliation to prevent potential drug-drug interactions.

To determine the appropriate treatment, researchers at Johns Hopkins University have developed the revised Birmingham score, which can be used to clinically classify the patient's disease state.[43] All interprofessional healthcare team members must maintain accurate, updated patient records, ensuring all professionals involved in patient care have access to the same patient information. Open communication channels between all healthcare team members are crucial to successful interprofessional care.

In addition, care coordination is pivotal in ensuring seamless and efficient patient care. Physicians, advanced practitioners, nurses, pharmacists, social workers, and other healthcare professionals must collaborate closely to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by MPA.

Review Questions

Histopathological Changes in Microscopic Polyangiitis Showing Fibrosis

Figure

Histopathological Changes in Microscopic Polyangiitis Showing Fibrosis. Contributed by Rian Kabir, MD

Typical Skin Manifestations Observed in Microscopic Polyangiitis

Figure

Typical Skin Manifestations Observed in Microscopic Polyangiitis. Contributed by R Kabir, MD

References

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. [PubMed: 23045170]

Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am. 2010 Aug;36(3):545-58. [PMC free article: PMC2917831] [PubMed: 20688249]

Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G, Martellucci S, Turchetta R, Longo L, De Vincentiis M. Goodpasture's syndrome: a clinical update. Autoimmun Rev. 2015 Mar;14(3):246-53. [PubMed: 25462583]

Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006 Dec;2(12):661-70. [PubMed: 17133251]

de Lind van Wijngaarden RA, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, Mahr AD, Niles JL, de Heer E, Bruijn JA, Bajema IM. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol. 2008 Jan;3(1):237-52. [PubMed: 18077783]

Walulik A, Łysak K, Błaszkiewicz M, Górecki I, Gomułka K. The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies. Int J Mol Sci. 2023 Dec 07;24(24) [PMC free article: PMC10743134] [PubMed: 38139045]

Kain R, Tadema H, McKinney EF, Benharkou A, Brandes R, Peschel A, Hubert V, Feenstra T, Sengölge G, Stegeman C, Heeringa P, Lyons PA, Smith KG, Kallenberg C, Rees AJ. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol. 2012 Mar;23(3):556-66. [PMC free article: PMC3294304] [PubMed: 22323643]

Jennette JC, Nachman PH. ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol. 2017 Oct 06;12(10):1680-1691. [PMC free article: PMC5628710] [PubMed: 28842398]

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012 Jul 19;367(3):214-23. [PMC free article: PMC3773907] [PubMed: 22808956]

Wakamatsu K, Mitsuhashi Y, Yamamoto T, Tsuboi R. Propylthiouracil-induced antineutrophil cytoplasmic antibody positive vasculitis clinically mimicking pyoderma gangrenosum. J Dermatol. 2012 Aug;39(8):736-8. [PubMed: 22132781]

Pendergraft WF, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014 Jan;26(1):42-9. [PubMed: 24276086]

Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study. Arthritis Rheumatol. 2017 Dec;69(12):2338-2350. [PMC free article: PMC5711593] [PubMed: 28881446]

Massicotte-Azarniouch D, Herrera CA, Jennette JC, Falk RJ, Free ME. Mechanisms of vascular damage in ANCA vasculitis. Semin Immunopathol. 2022 May;44(3):325-345. [PMC free article: PMC9064952] [PubMed: 35254509]

Frankel SK, Schwarz MI. The pulmonary vasculitides. Am J Respir Crit Care Med. 2012 Aug 01;186(3):216-24. [PubMed: 22679011]

Sun L, Wang H, Jiang X, Mo Y, Yue Z, Huang L, Liu T. Clinical and pathological features of microscopic polyangiitis in 20 children. J Rheumatol. 2014 Aug;41(8):1712-9. [PubMed: 24986845]

Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC., European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002 Jan;61(1):80-9. [PubMed: 11786087]

Lababidi MH, Odigwe C, Okolo C, Elhassan A, Iroegbu N. Microscopic polyangiitis causing diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. Proc (Bayl Univ Med Cent). 2015 Oct;28(4):469-71. [PMC free article: PMC4569227] [PubMed: 26424944]

Wang H, Sun L, Tan W. Clinical features of children with pulmonary microscopic polyangiitis: report of 9 cases. PLoS One. 2015;10(4):e0124352. [PMC free article: PMC4414499] [PubMed: 25923706]

Wilke L, Prince-Fiocco M, Fiocco GP. Microscopic polyangiitis: a large single-center series. J Clin Rheumatol. 2014 Jun;20(4):179-82. [PubMed: 24847742]

Karras A. Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy. Semin Respir Crit Care Med. 2018 Aug;39(4):459-464. [PubMed: 30404112]

Barowka SE, Perrine TR, Hughes K. "I'm coughing up blood". J Miss State Med Assoc. 2016 Nov;57(11):354-356. [PubMed: 30281235]

Kluger N, Pagnoux C, Guillevin L, Francès C., French Vasculitis Study Group. Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. Br J Dermatol. 2008 Sep;159(3):615-20. [PubMed: 18647311]

Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus. 1998;7(4):238-58. [PubMed: 9643314]

Gibson LE. Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. Int J Dermatol. 2022 Dec;61(12):1442-1451. [PubMed: 35599359]

Eriksson P, Segelmark M, Hallböök O. Frequency, Diagnosis, Treatment, and Outcome of Gastrointestinal Disease in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. J Rheumatol. 2018 Apr;45(4):529-537. [PubMed: 29419474]

Hattori N, Mori K, Misu K, Koike H, Ichimura M, Sobue G. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol. 2002 Jul;29(7):1408-14. [PubMed: 12136898]

Xu J, Ding Y, Qu Z, Yu F. Posterior Reversible Encephalopathy Syndrome in a Patient With Microscopic Polyangiitis: A Case Report and Literature Review. Front Med (Lausanne). 2021;8:792744. [PMC free article: PMC8772586] [PubMed: 35071272]

Ku BD, Shin HY. Multiple bilateral non-hemorrhagic cerebral infarctions associated with microscopic polyangiitis. Clin Neurol Neurosurg. 2009 Dec;111(10):904-6. [PubMed: 19733002]

Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest. 2003 Jan;123(1):297-301. [PubMed: 12527637]

Iida T, Adachi T, Tabeya T, Nakagaki S, Yabana T, Goto A, Kondo Y, Kasai K. Rare type of pancreatitis as the first presentation of anti-neutrophil cytoplasmic antibody-related vasculitis. World J Gastroenterol. 2016 Feb 21;22(7):2383-90. [PMC free article: PMC4735013] [PubMed: 26900301]

Sassi SB, Ghorbel IB, Mizouni H, Houman MH, Hentati F. Microscopic polyangiitis presenting with peripheral and central neurological manifestations. Neurol Sci. 2011 Aug;32(4):727-9. [PubMed: 21681367]

Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A, Little MA, Luqmani RA, Mahr A, Merkel PA, Mohammad AJ, Monti S, Mukhtyar CB, Musial J, Price-Kuehne F, Segelmark M, Teng YKO, Terrier B, Tomasson G, Vaglio A, Vassilopoulos D, Verhoeven P, Jayne D. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 02;83(1):30-47. [PubMed: 36927642]

Schirmer JH, Sanchez-Alamo B, Hellmich B, Jayne D, Monti S, Luqmani RA, Tomasson G. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis. RMD Open. 2023 Jul;9(3) [PMC free article: PMC10364171] [PubMed: 37479496]

Jayne DRW, Merkel PA, Schall TJ, Bekker P., ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021 Feb 18;384(7):599-609. [PubMed: 33596356]

Casal Moura M, Gauckler P, Anders HJ, Bruchfeld A, Fernandez-Juarez GM, Floege J, Frangou E, Goumenos D, Segelmark M, Turkmen K, van Kooten C, Tesar V, Geetha D, Fervenza FC, Jayne DRW, Stevens KI, Kronbichler A. Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations. Nephrol Dial Transplant. 2023 Oct 31;38(11):2637-2651. [PMC free article: PMC10615627] [PubMed: 37164940]

Walsh M, Collister D, Zeng L, Merkel PA, Pusey CD, Guyatt G, Au Peh C, Szpirt W, Ito-Hara T, Jayne DRW., Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis BMJ Rapid Recommendations Group. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ. 2022 Feb 25;376:e064604. [PubMed: 35217545]

Ward ND, Cosner DE, Lamb CA, Li W, Macknis JK, Rooney MT, Zhang PL. Top Differential Diagnosis Should Be Microscopic Polyangiitis in ANCA-Positive Patient with Diffuse Pulmonary Hemorrhage and Hemosiderosis. Case Rep Pathol. 2014;2014:286030. [PMC free article: PMC4265693] [PubMed: 25525543]

Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020 Aug;16(8):437-447. [PubMed: 32286516]

Haldar S, Dru C, Bhowmick NA. Mechanisms of hemorrhagic cystitis. Am J Clin Exp Urol. 2014;2(3):199-208. [PMC free article: PMC4219308] [PubMed: 25374922]

Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, Kullman J, Lyons PA, Merkel PA, Savage COS, Specks U, Kain R. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug 27;6(1):71. [PubMed: 32855422]

Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, Jayne D, Mahr A, Westman K, Luqmani R. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015 Mar;54(3):471-81. [PubMed: 25205825]

Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, Jayne D, Mahr A, Westman K, Luqmani R. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015 Jan;74(1):177-84. [PubMed: 24243925]

Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA., International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001 Apr;44(4):912-20. [PubMed: 11318006]

Disclosure: Muhammad Hashmi declares no relevant financial relationships with ineligible companies.

Disclosure: Vardhmaan Jain declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Rout declares no relevant financial relationships with ineligible companies.